1. Home
  2. CLW vs ALDX Comparison

CLW vs ALDX Comparison

Compare CLW & ALDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Clearwater Paper Corporation

CLW

Clearwater Paper Corporation

HOLD

Current Price

$14.67

Market Cap

265.6M

ML Signal

HOLD

Logo Aldeyra Therapeutics Inc.

ALDX

Aldeyra Therapeutics Inc.

HOLD

Current Price

$4.78

Market Cap

317.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CLW
ALDX
Founded
1926
2004
Country
United States
United States
Employees
3710
N/A
Industry
Paper
Biotechnology: Pharmaceutical Preparations
Sector
Basic Materials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
265.6M
317.7M
IPO Year
2008
2014

Fundamental Metrics

Financial Performance
Metric
CLW
ALDX
Price
$14.67
$4.78
Analyst Decision
Buy
Strong Buy
Analyst Count
3
2
Target Price
$23.00
$9.50
AVG Volume (30 Days)
242.3K
827.6K
Earning Date
05-20-2026
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
40.43
EPS
N/A
N/A
Revenue
$1,555,400,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$4.20
$123.43
P/E Ratio
N/A
N/A
Revenue Growth
12.42
N/A
52 Week Low
$13.84
$1.18
52 Week High
$30.96
$7.19

Technical Indicators

Market Signals
Indicator
CLW
ALDX
Relative Strength Index (RSI) 36.69 42.44
Support Level N/A $4.74
Resistance Level $18.85 $5.70
Average True Range (ATR) 0.73 0.33
MACD -0.01 -0.07
Stochastic Oscillator 24.27 30.55

Price Performance

Historical Comparison
CLW
ALDX

About CLW Clearwater Paper Corporation

Clearwater Paper Corp is engaged in the manufacturing and supplier of Solid Bleached Sulfate (SBS) paperboard packaging products. The company products includes: SBS paperboard which is a premium paperboard grade that is frequently used to produce folding cartons, food service, commercial printing items. It generates maximum revenue from Pulp and Paperboard segment. Company operate in United States and have globalized access too. Geographically, it derives maximum revenue from the United States.

About ALDX Aldeyra Therapeutics Inc.

Aldeyra Therapeutics Inc is a biotechnology company engaged in developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated and metabolic diseases. The company's product candidate, Reproxalap, is a treatment in late-stage development for dry eye disease and allergic conjunctivitis. In addition, it also has additional product candidates in development for proliferative vitreoretinopathy, primary vitreoretinal lymphoma and other retinal diseases, autoimmune disease, and cancer. Company products includes ADX248, ADX743, ADX631, ADX246, ADX629, ADX2191.

Share on Social Networks: